Approximately 701 patients will participate in this study worldwide and it is estimated to be completed in June 2018. This study is currently recruiting participants. Read more.
![[Unlock]](https://browardliving.org/wp-content/uploads/2017/08/human_box.png "Unlock")
I AM A HUMAN AND NOT A ROBOT![[Locked]](https://browardliving.org/wp-content/uploads/2017/02/lock.png "Locked")
⇧ Checking the box is REQUIRED for validation.
What is the purpose of this study?
This is a phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of MLN9708 versus placebo when added to lenalidomide and dexamethasone (LenDex) in patients with Newly Diagnosed Multiple Myeloma (NDMM) who are not eligible for stem cell transplant.
Who is eligible for this study?
Male or female patients 18 years or older diagnosed with Multiple Myeloma according to standard criteria who have not received prior treatment. See details.